Identification of novel DNA methylation inhibitors via a two-component reporter gene system

Yi Shiuan Lin, Arthur Y. Shaw, Shi Gang Wang, Chia Chen Hsu, I. Wen Teng, Min Jen Tseng, Hui-ming Huang, Ching Shih Chen, Yu Wei Leu, Shu Huei Hsiao

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background. Targeting abnormal DNA methylation represents a therapeutically relevant strategy for cancer treatment as demonstrated by the US Food and Drug Administration approval of the DNA methyltransferase inhibitors azacytidine and 5-aza-2′-deoxycytidine for the treatment of myelodysplastic syndromes. But their use is associated with increased incidences of bone marrow suppression. Alternatively, procainamide has emerged as a potential DNA demethylating agent for clinical translation. While procainamide is much safer than 5-aza-2′-deoxycytidine, it requires high concentrations to be effective in DNA demethylation in suppressing cancer cell growth. Thus, our laboratories have embarked on the pharmacological exploitation of procainamide to develop potent DNA methylation inhibitors through lead optimization. Methods. We report the use of a DNA methylation two-component enhanced green fluorescent protein reporter system as a screening platform to identify novel DNA methylation inhibitors from a compound library containing procainamide derivatives. Results. A lead agent IM25, which exhibits substantially higher potency in GSTp1 DNA demethylation with lower cytotoxicity in MCF7 cells relative to procainamide and 5-aza-2′-deoxycytidine, was identified by the screening platform. Conclusions. Our data provide a proof-of-concept that procainamide could be pharmacologically exploited to develop novel DNA methylation inhibitors, of which the translational potential in cancer therapy/prevention is currently under investigation.

Original languageEnglish (US)
Article number3
JournalJournal of Biomedical Science
Volume18
Issue number1
DOIs
StatePublished - 2011
Externally publishedYes

Fingerprint

Procainamide
decitabine
DNA Methylation
Reporter Genes
Genes
DNA
Screening
Drug Approval
Azacitidine
Neoplasms
Oncology
Myelodysplastic Syndromes
MCF-7 Cells
Methyltransferases
Cell growth
Cytotoxicity
Libraries
Bone
Bone Marrow
Pharmacology

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Molecular Biology
  • Cell Biology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism
  • Pharmacology (medical)

Cite this

Lin, Y. S., Shaw, A. Y., Wang, S. G., Hsu, C. C., Teng, I. W., Tseng, M. J., ... Hsiao, S. H. (2011). Identification of novel DNA methylation inhibitors via a two-component reporter gene system. Journal of Biomedical Science, 18(1), [3]. https://doi.org/10.1186/1423-0127-18-3

Identification of novel DNA methylation inhibitors via a two-component reporter gene system. / Lin, Yi Shiuan; Shaw, Arthur Y.; Wang, Shi Gang; Hsu, Chia Chen; Teng, I. Wen; Tseng, Min Jen; Huang, Hui-ming; Chen, Ching Shih; Leu, Yu Wei; Hsiao, Shu Huei.

In: Journal of Biomedical Science, Vol. 18, No. 1, 3, 2011.

Research output: Contribution to journalArticle

Lin, YS, Shaw, AY, Wang, SG, Hsu, CC, Teng, IW, Tseng, MJ, Huang, H, Chen, CS, Leu, YW & Hsiao, SH 2011, 'Identification of novel DNA methylation inhibitors via a two-component reporter gene system', Journal of Biomedical Science, vol. 18, no. 1, 3. https://doi.org/10.1186/1423-0127-18-3
Lin, Yi Shiuan ; Shaw, Arthur Y. ; Wang, Shi Gang ; Hsu, Chia Chen ; Teng, I. Wen ; Tseng, Min Jen ; Huang, Hui-ming ; Chen, Ching Shih ; Leu, Yu Wei ; Hsiao, Shu Huei. / Identification of novel DNA methylation inhibitors via a two-component reporter gene system. In: Journal of Biomedical Science. 2011 ; Vol. 18, No. 1.
@article{6506223fda5b40f4b3318d8cbe2c89dd,
title = "Identification of novel DNA methylation inhibitors via a two-component reporter gene system",
abstract = "Background. Targeting abnormal DNA methylation represents a therapeutically relevant strategy for cancer treatment as demonstrated by the US Food and Drug Administration approval of the DNA methyltransferase inhibitors azacytidine and 5-aza-2′-deoxycytidine for the treatment of myelodysplastic syndromes. But their use is associated with increased incidences of bone marrow suppression. Alternatively, procainamide has emerged as a potential DNA demethylating agent for clinical translation. While procainamide is much safer than 5-aza-2′-deoxycytidine, it requires high concentrations to be effective in DNA demethylation in suppressing cancer cell growth. Thus, our laboratories have embarked on the pharmacological exploitation of procainamide to develop potent DNA methylation inhibitors through lead optimization. Methods. We report the use of a DNA methylation two-component enhanced green fluorescent protein reporter system as a screening platform to identify novel DNA methylation inhibitors from a compound library containing procainamide derivatives. Results. A lead agent IM25, which exhibits substantially higher potency in GSTp1 DNA demethylation with lower cytotoxicity in MCF7 cells relative to procainamide and 5-aza-2′-deoxycytidine, was identified by the screening platform. Conclusions. Our data provide a proof-of-concept that procainamide could be pharmacologically exploited to develop novel DNA methylation inhibitors, of which the translational potential in cancer therapy/prevention is currently under investigation.",
author = "Lin, {Yi Shiuan} and Shaw, {Arthur Y.} and Wang, {Shi Gang} and Hsu, {Chia Chen} and Teng, {I. Wen} and Tseng, {Min Jen} and Hui-ming Huang and Chen, {Ching Shih} and Leu, {Yu Wei} and Hsiao, {Shu Huei}",
year = "2011",
doi = "10.1186/1423-0127-18-3",
language = "English (US)",
volume = "18",
journal = "Journal of Biomedical Science",
issn = "1021-7770",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Identification of novel DNA methylation inhibitors via a two-component reporter gene system

AU - Lin, Yi Shiuan

AU - Shaw, Arthur Y.

AU - Wang, Shi Gang

AU - Hsu, Chia Chen

AU - Teng, I. Wen

AU - Tseng, Min Jen

AU - Huang, Hui-ming

AU - Chen, Ching Shih

AU - Leu, Yu Wei

AU - Hsiao, Shu Huei

PY - 2011

Y1 - 2011

N2 - Background. Targeting abnormal DNA methylation represents a therapeutically relevant strategy for cancer treatment as demonstrated by the US Food and Drug Administration approval of the DNA methyltransferase inhibitors azacytidine and 5-aza-2′-deoxycytidine for the treatment of myelodysplastic syndromes. But their use is associated with increased incidences of bone marrow suppression. Alternatively, procainamide has emerged as a potential DNA demethylating agent for clinical translation. While procainamide is much safer than 5-aza-2′-deoxycytidine, it requires high concentrations to be effective in DNA demethylation in suppressing cancer cell growth. Thus, our laboratories have embarked on the pharmacological exploitation of procainamide to develop potent DNA methylation inhibitors through lead optimization. Methods. We report the use of a DNA methylation two-component enhanced green fluorescent protein reporter system as a screening platform to identify novel DNA methylation inhibitors from a compound library containing procainamide derivatives. Results. A lead agent IM25, which exhibits substantially higher potency in GSTp1 DNA demethylation with lower cytotoxicity in MCF7 cells relative to procainamide and 5-aza-2′-deoxycytidine, was identified by the screening platform. Conclusions. Our data provide a proof-of-concept that procainamide could be pharmacologically exploited to develop novel DNA methylation inhibitors, of which the translational potential in cancer therapy/prevention is currently under investigation.

AB - Background. Targeting abnormal DNA methylation represents a therapeutically relevant strategy for cancer treatment as demonstrated by the US Food and Drug Administration approval of the DNA methyltransferase inhibitors azacytidine and 5-aza-2′-deoxycytidine for the treatment of myelodysplastic syndromes. But their use is associated with increased incidences of bone marrow suppression. Alternatively, procainamide has emerged as a potential DNA demethylating agent for clinical translation. While procainamide is much safer than 5-aza-2′-deoxycytidine, it requires high concentrations to be effective in DNA demethylation in suppressing cancer cell growth. Thus, our laboratories have embarked on the pharmacological exploitation of procainamide to develop potent DNA methylation inhibitors through lead optimization. Methods. We report the use of a DNA methylation two-component enhanced green fluorescent protein reporter system as a screening platform to identify novel DNA methylation inhibitors from a compound library containing procainamide derivatives. Results. A lead agent IM25, which exhibits substantially higher potency in GSTp1 DNA demethylation with lower cytotoxicity in MCF7 cells relative to procainamide and 5-aza-2′-deoxycytidine, was identified by the screening platform. Conclusions. Our data provide a proof-of-concept that procainamide could be pharmacologically exploited to develop novel DNA methylation inhibitors, of which the translational potential in cancer therapy/prevention is currently under investigation.

UR - http://www.scopus.com/inward/record.url?scp=78650972028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650972028&partnerID=8YFLogxK

U2 - 10.1186/1423-0127-18-3

DO - 10.1186/1423-0127-18-3

M3 - Article

VL - 18

JO - Journal of Biomedical Science

JF - Journal of Biomedical Science

SN - 1021-7770

IS - 1

M1 - 3

ER -